['chemotherapy-induced nausea and vomiting']
['rolapitant']

        Main Inclusion Criteria:

          -  Subject must be a healthy male or female aged 18 to 55 years at Screening

          -  A female subject must have a negative pregnancy test at Screening and on Day -1.

          -  A female subject of childbearing potential must agree to use an accepted method of
             birth control (excluding hormonal birth control methods) from Screening through 30
             days after final study drug administration.

          -  Subject must have a body mass index (BMI) from 18.5 to 32.0 kg/m2 and a weight of

             ≥ 50 kg at Screening.

          -  Subject must be able to provide informed consent after risks and benefits have been
             explained. Subject must also be willing and able to comply with the protocol
             requirements.

          -  Subject must be in general good health as determined by the Investigator based on
             pre-study medical, medication, and surgical history; physical examination; and
             clinical laboratory tests.

        Main Exclusion Criteria:

          -  Subject must not have been dosed with test drug or blinded study drug in another
             investigational study within 30 days or 5 half-lives of the biologic activity of the
             test drug, whichever is longer, before the time of first study dose.

          -  Subject must not have a history of hypersensitivity to rolapitant IV or any of its
             excipients or who have completed a study visit as part of a previous rolapitant study
             within the 6 months prior to first study drug administration (Day

          -  Subject must not have poor venous access or consider venipuncture intolerable.

          -  Subject must not have a history of significant complications or anxiety associated
             with the IV administration of medications that, in the opinion of the Investigator,
             could make the subject unable to complete dosing requirements.

          -  Subject must not be pregnant or lactating.
      